Indivior Pharmaceuticals (INDV) Deferred Taxes (2024 - 2026)

Indivior Pharmaceuticals' Deferred Taxes history runs 3 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• On a quarterly basis, Deferred Taxes rose 1450.0% year-over-year to $27.0 million in Q1 2026; TTM through Mar 2026 was -$17.0 million, a 950.0% decrease from a year earlier, with the FY2025 full-year figure at -$46.0 million, down 757.14% from the prior year.
• Deferred Taxes advanced to $27.0 million in Q1 2026 per INDV's latest filing, from -$38.0 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $37.0 million in Q4 2024 and bottomed at -$38.0 million in Q4 2025.
• The 3-year median for Deferred Taxes is -$2.0 million (2025), against an average of -$1.3 million.
• Across the five-year window, Deferred Taxes tumbled 202.7% in 2025 and surged 1450.0% in 2026, its largest moves.
• Year by year, Deferred Taxes stood at $37.0 million in 2024, then tumbled by 202.7% to -$38.0 million in 2025, then soared by 171.05% to $27.0 million in 2026.
• Per Business Quant, the three latest INDV Deferred Taxes figures stand at $27.0 million (Q1 2026), -$38.0 million (Q4 2025), and -$15.0 million (Q3 2025).